Osimertinib (AZD9291)

For research use only. Not for use in humans.

目录号：S7297 别名： Mereletinib

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib)是口服不可逆的，突变选择性EGFR抑制剂，在 LoVo细胞中对Exon 19 缺失的 EGFR，L858R/T790M EGFR，和 WT EGFR的IC50分别为12.92，11.44 和 493.8 nM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1203.93	现货
5mg	RMB 807.34	现货
10mg	RMB 1105.43	现货
100mg	RMB 5733.0	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Osimertinib (AZD9291)发表文献261篇：

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cell, 2020, 182(5):1232-1251.e22

PubMed: 32822576 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4789

PubMed: 34373451 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2346

PubMed: 33879767 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5919

PubMed: 34635651 ( click the link to review the publication )

Cancer Res, 2021, canres.1153.2021

PubMed: 34301758 ( click the link to review the publication )

Cancer Res, 2021, canres.CAN-21-2426-E.2021

PubMed: 34548332 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Cancers (Basel), 2021, 13(12)2987

PubMed: 34203709 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3906

PubMed: 34359807 ( click the link to review the publication )

Arch Toxicol, 2021, 10.1007/s00204-021-03147-4

PubMed: 34455456 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0965.2020

PubMed: 34158345 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(5):6890-6903

PubMed: 33621951 ( click the link to review the publication )

Pharmacol Res, 2021, 170:105701

PubMed: 34087353 ( click the link to review the publication )
Transl Lung Cancer Res, 2021, 10(8):3659-3670

PubMed: 34584864 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1963-1974

PubMed: 33544933 ( click the link to review the publication )

Cancer Sci, 2021, 112(9):3784-3795

PubMed: 34145930 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1853-1864

PubMed: 33410241 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):29

PubMed: 33723247 ( click the link to review the publication )

Oncogenesis, 2021, 10(7):56

PubMed: 34315851 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1869(1):119144

PubMed: 34599981 ( click the link to review the publication )

Lung Cancer, 2021, 158:137-145

PubMed: 34214933 ( click the link to review the publication )

Front Oncol, 2021, 11:665045

PubMed: 34168988 ( click the link to review the publication )

Front Oncol, 2021, 11:711043

PubMed: 34490108 ( click the link to review the publication )

Biochem Pharmacol, 2021, 190:114642

PubMed: 34077739 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(8)4005

PubMed: 33924522 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00691-8

PubMed: 34035487 ( click the link to review the publication )

Ann Transl Med, 2021, 9(14):1150

PubMed: 34430591 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2021, 419:115518

PubMed: 33812963 ( click the link to review the publication )

Cancer Res Treat, 2021, 10.4143/crt.2021.385

PubMed: 33940786 ( click the link to review the publication )

Toxicol Lett, 2021, 348:10-17

PubMed: 34044055 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 571:38-45

PubMed: 34303194 ( click the link to review the publication )

Thorac Cancer, 2021, 12(11):1690-1698

PubMed: 33939301 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13931

PubMed: 33710795 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )
Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

BMC Pulm Med, 2021, 21(1):163

PubMed: 33992097 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Exp Ther Med, 2021, 21(6):654

PubMed: 33968184 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Lung Cancer, 2021, 154:84-91

PubMed: 33631449 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):65

PubMed: 34267282 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):32

PubMed: 33863983 ( click the link to review the publication )

CU Digital Repository, 2021, N/A

PubMed: None ( click the link to review the publication )

Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Sci Immunol, 2020, 31;5(43) pii: eaav3937

PubMed: 32005679 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2321

PubMed: 31953310 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Theranostics, 2020, 15;10(14):6122-6135

PubMed: 32483443 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4655-4667

PubMed: 32873635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 28;483:46-58

PubMed: 32272148 ( click the link to review the publication )

Cancers (Basel), 2020, 13(1)E111

PubMed: 33396393 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32183160 ( click the link to review the publication )
Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Hum Mol Genet, 2020, ddaa268

PubMed: 33326033 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Lung Cancer, 2020, 5;145:48-57

PubMed: 32408132 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):366

PubMed: 32355810 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22899

PubMed: 31916386 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

J Oncol, 2020, 17;2020:6249829

PubMed: 32256584 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):169

PubMed: 33287873 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Nat Cancer, 2020, 1(3):359-369

PubMed: 33345196 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:652

PubMed: 32793596 ( click the link to review the publication )

Pharmaceutics, 2020, 12(10)E939

PubMed: 33008019 ( click the link to review the publication )

Cells, 2020, 9(12)E2596

PubMed: 33287368 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0443-1

PubMed: 32704041 ( click the link to review the publication )
Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0457-8

PubMed: 32678313 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11236

PubMed: 32641854 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(4):656-671

PubMed: 30578931 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3329-3340

PubMed: 30770351 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz206

PubMed: 31678994 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Biomaterials, 2019, 219:119400

PubMed: 31398570 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers, 2019, 11(3)

PubMed: 30818860 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):112-126

PubMed: 30322949 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(9):1593-1601

PubMed: 31253648 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Lung Cancer, 2019, 127:146-152

PubMed: 30642543 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(11):7427-7437

PubMed: 31454149 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(12):2607-2614

PubMed: 31754333 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:3419-3432

PubMed: 31114376 ( click the link to review the publication )

Ann Transl Med, 2019, 7(22):651

PubMed: 31930052 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 379:114662

PubMed: 31301315 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Thorac Cancer, 2019, 10(10):1868-1878

PubMed: 31486270 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):955-961

PubMed: 31289574 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 7(1):161-184

PubMed: 30522949 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )
Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):264-270

PubMed: 31109435 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):915-925

PubMed: 29702287 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(22):5610-5621

PubMed: 29967248 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 10.1158/0008-5472.CAN-18-0505

PubMed: 30026325 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):740-750

PubMed: 29467275 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2257-2265

PubMed: 30049789 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(1):99-109

PubMed: 29269566 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Cell Neurosci, 2018, 12:21

PubMed: 29456493 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )
Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(3):239-247

PubMed: 29333953 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 10.1007/s00432-018-2668-7

PubMed: 29797219 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Environ Toxicol, 2018, 33(11):1153-1159

PubMed: 30136359 ( click the link to review the publication )

Radiat Res, 2018, 189(3):283-291

PubMed: 29332537 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Sci Transl Med, 2017, 9(415)

PubMed: 29118262 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(5):884-889

PubMed: 28088511 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )
Neuro Oncol, 2017, 19(12):1628-1639

PubMed: 28575494 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3527-3539

PubMed: 28522751 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472

PubMed: 28202511 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1200-1211

PubMed: 28082405 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.21536

PubMed: 28199182 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(3):506-515

PubMed: 28138027 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28388009 ( click the link to review the publication )

J Mol Biol, 2017, 429(14):2211-2230

PubMed: 28539250 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:510-527

PubMed: 28987609 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(11):1542-1550

PubMed: 28784613 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

Lung Cancer, 2017, 108:96-102

PubMed: 28625657 ( click the link to review the publication )
Lung Cancer, 2017, 109:1-8

PubMed: 28577937 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 321:18-26

PubMed: 28237877 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5281-5288

PubMed: 29138581 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

J Vis Exp, 2017, (126)

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

Oncotarget, 2017, 8(62):104894-104912

PubMed: 29285221 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15441

PubMed: 29133857 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Mol Cell, 2016, 63(3):526-38

PubMed: 27453044 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )
Cancer Immunol Res, 2016, 4(11):936-947

PubMed: 27680026 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Med Chem, 2016, 59(13):6187-200

PubMed: 27266526 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23608-32

PubMed: 27015562 ( click the link to review the publication )

Sci Rep, 2016, 6:37997

PubMed: 27897231 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5305-13

PubMed: 26206867 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Sci Signal, 2015, 8(379):ra53

PubMed: 26038598 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143333

PubMed: 26580964 ( click the link to review the publication )

J Natl Compr Canc Netw, 2013, 11(10):1249-61

PubMed: 24142826 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Expert Opin Pharmacother, 2010, 11(8):1263-76

PubMed: 20429667 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

靶点

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外研究

与体外野生型相比，在突变EGFR 细胞系中AZD9291能更有效的抑制增殖。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	MYrGeY5kfGmxbjDBd5NigQ>?	M4HqXFUxKG6P	Moj2NlQhcA>?	NXX5TmExTE2VTx?=	MlexbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	NXn0fWltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1	NGXoN49HfW6ldHnvckBCe3OjeR?=	NUW5UG84PTBibl2=	M3jmelI1KGh?	NHXGWplFVVOR	NEexbIVqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=>	MmPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	NUfnb3RwTnWwY4Tpc44hSXO\|YYm=	NXz3[pFGPTBibl2=	NGTzbpgzPCCq	M4\0U2ROW09?	M2DGWYlv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/BRc1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXDO2Q2PTBibl2=	Mm\uNVAh\A>?	M2\Vc2ROW09?	M1m0TIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?=	MkXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
PC-9/ERc1	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XreFUxKG6P	NHjlUG4yOCCm	MVnEUXNQ	Ml63bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	Mo\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	NIfZUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFno[3k2OCCwTR?=	NFPsOnoyOCCm	NG\4botFVVOR	NHHNXXpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	NF[0b4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC9 GR4	MlXTSpVv[3Srb36gRZN{[Xl?	M4Xa[VAuOTBizszN	MnrQO\|IhcA>?		M4rse4lvcGmkaYTzxsBGT0[UIIDoc5NxcG:{eXzheIlwdiCjbnSg[I94dnO2cnXhcUB{cWewYXzpcofDqA>?	MnrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9	Mne3SpVv[3Srb36gRZN{[Xl?	M{HJblAuOTBizszN	NWPJfHdoPzJiaB?=		NFK4RVdqdmirYnn0d{BYXCCHR1\SJIF1KGyxdzDjc45k\W62cnH0bY9vew>?	MoL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9 GR4	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHtXGJJOC1zMDFOwG0>	MVy3NkBp		MVLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
BAF3	NH;INWRHfW6ldHnvckBie3OjeR?=		MXe3NkBp		MkPBS2k2OCB;IECuNFAxOyEQvF2=	NWO2dWp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NEC5SIpHfW6ldHnvckBie3OjeR?=		MkHrO\|IhcA>?		MonCS2k2OCB;IECuNFAxOyEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	MYfGeY5kfGmxbjDhd5NigQ>?		MkLCO\|IhcA>?		MYrHTVUxKD1iMD6wNFEh\|ryP	NHT0S4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	M1nVS2Z2dmO2aX;uJIF{e2G7		MVi3NkBp		M3L4[mdKPTBiPTCwMlAxOSEQvF2=	NX3rdGNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	NWfqSlY3TnWwY4Tpc44h[XO\|YYm=		M{LsPVczKGh?		M4XINmdKPTBiPTCwMlAxOiEQvF2=	M3;QclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	NE\rTmNHfW6ldHnvckBie3OjeR?=		MnXjOEBp		MmfwSWM2OCB;IECuNFAzKM7:TR?=	NYXRW5pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	M4PBRWZ2dmO2aX;uJIF{e2G7		NFHvfGg{KGh?		M1TqXmlEPTBiPTCwMlAxOjVizszN	NFLGe5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H1975	MnXhSpVv[3Srb36gZZN{[Xl?		M4fveVMhcA>?		MmDOTWM2OCB;IECuNFAzPSEQvF2=	NWP0UXBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N\|M5OjlpPkK3OFM{QDJ7PD;hQi=>
H3255	MVnGeY5kfGmxbjDhd5NigQ>?		NH\VPW4{KGh?		NXnZ[G9XUUN3MDC9JFAvODB2MTFOwG0>	NVXUb3IzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N\|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975	M2PDVGZ2dmO2aX;uJIF{e2G7		NE\0WVM4OiCq		MmDaS2k2OCB;IECuNFA2KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	M2HY[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M33yeVczKGh?		MWLJR\|UxKD1iMD6wNFY2KM7:TR?=	MorKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
NCI-H1975	NVPNemJESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MmG3O\|IhcA>?		NUnl[2ViUUN3MDC9JFAvODFyNTFOwG0>	M3i3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
Sf21	NFnlS3FHfW6ldHnvckBie3OjeR?=				Mmi3TWM2OCB;IECuNFEzKM7:TR?=	NGT3ZpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
PC9-DRH	NIjJNodHfW6ldHnvckBie3OjeR?=		NIXjc44zKGh?		MUTJR\|UxKD1iMD6wNVMh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
BAF3	MlvySpVv[3Srb36gZZN{[Xl?		M3jvTVczKGh?		Mn;MS2k2OCB;IECuNFE{KM7:TR?=	Mm[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	MVrGeY5kfGmxbjDhd5NigQ>?		M3\STVk3KGh?		NILwbZFGSzVyIE2gNE4xOTRizszN	M3npV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
HCC827	M2PNdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIjW[Fk6PiCq		NYPZcZN1TUN3MDC9JFAvODF2IN88US=>	NHH6fGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	NGPFSXpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NUTofVBDQTZiaB?=		NInmZ49GSzVyIE2gNE4xOTRizszN	M3vLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	NYHzfItXTnWwY4Tpc44h[XO\|YYm=		M3vkWFIhcA>?		NV7tSZNCUUN3MDC9JFAvODF3IN88US=>	NEe3[5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
H1975	M3Lr[mZ2dmO2aX;uJIF{e2G7		NHPBfFczKGh?		NHrt[FhKSzVyIE2gNE4xOTVizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
PC9	MlzwSpVv[3Srb36gZZN{[Xl?		NV\aZlc5OiCq		Mo\ETWM2OCB;IECuNFE4KM7:TR?=	M4\ld\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
NCI-H1975	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NWX1R4xPPzJiaB?=		MmLsTWM2OCB;IECuNFE6KM7:TR?=	NWPNRplzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
NCI-H1975	NUPDeoxiTnWwY4Tpc44h[XO\|YYm=		MV:5OkBp		NWfKWGJYTUN3MDC9JFAvODF7IN88US=>	NUO3b3VPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
NCI-H1975	NWjPcWRiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NECxOlE6PiCq		MYjFR\|UxKD1iMD6wNVkh\|ryP	MmXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
NCI-H1975	Mm\PRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3TufVczKGh?		NWHEPHJCUUN3MDC9JFAvODF7IN88US=>	NVexZWRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
HCC827	NEHEVFRHfW6ldHnvckBie3OjeR?=		MlLlNkBp		MVnJR\|UxKD1iMD6wNlMh\|ryP	M1qzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	Mln1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M17KNFczKGh?		NHPJUmZKSzVyIE2gNE4xOjNizszN	NILiUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
PC9	MnfCR5l1d3SxeHnjbZR6KGG\|c3H5		NXnifVh3PzJiaB?=		M{jSWmdKPTBiPTCwMlAzOyEQvF2=	NFuyW3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	NVjiWpRwS3m2b4TvfIlkcXS7IHHzd4F6		NW\oSGFOPzJiaB?=		NXvYWYpFT0l3MDC9JFAvODJ2IN88US=>	MorTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
HCC827	M3\zd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NYnVRVIxPzJiaB?=		NUfGUVI2UUN3MDC9JFAvODJ3NDFOwG0>	M2nZeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
HCC827	M3u2NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1S3ZVczKGh?		MWrJR\|UxKD1iMD6wNlch\|ryP	NV\leppkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
HCC827	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NH3kb\|E4OiCq		NF;MW\|FKSzVyIE2gNE4xOjdizszN	NXXyS2xvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975	NEP0UppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkfkO\|IhcA>?		MYXJR\|UxKD1iMD6wN{DPxE1?	M1rCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
H3255	MYDGeY5kfGmxbjDhd5NigQ>?		MkjYO\|IhcA>?		MoPHS2k2OCB;IECuNFM{KM7:TR?=	NVPzSY04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	M1flN2Z2dmO2aX;uJIF{e2G7		MkTHNkBp		MYLJR\|UxKD1iMD6wN\|Yh\|ryP	M1fUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	NH\TbINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MmXiO\|IhcA>?		NV7Ud4hZUUN3MDC9JFAvODRzIN88US=>	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{CxPVIoRjJ7N{OwNVkzRC:jPh?=
NCI-H1975	NIrVdWpHfW6ldHnvckBie3OjeR?=		M{PaS\|EhcA>?		NEHjXJhKSzVyIE2gNE4xPDFizszN	MljMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
BAF3	NFnIbHBHfW6ldHnvckBie3OjeR?=		NUHSWHNHPCCq		NEG1UWFGSzVyIE2gNE4xPDNizszN	NWL6fGlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M{W1WlczKGh?		NYP0[3I2UUN3MDC9JFAvODR5MjFOwG0>	M4rOSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
NCI-H1975	NGHmTWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NEDiOHg4OiCq		MkTQTWM2OCB;IECuNFUzKM7:TR?=	MlLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N\|koRjJ5MUOxOlM6RC:jPh?=
PC9	NFjtWWxHfW6ldHnvckBie3OjeR?=		M{PMU\|IhcA>?		MWjJR\|UxKD1iMD6wOVYh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975	Mnq4R5l1d3SxeHnjbZR6KGG\|c3H5		NVX1U2pyPzJiaB?=		MlzxTWM2OCB;IECuNFYh\|ryP	MnPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?				MnrjTWM2OCB;IECuNFYyPiEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
NCI-H1975	MonMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MXLJR\|UxKD1iMD6wOlch\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
HaCaT	M3\QO2Z2dmO2aX;uJIF{e2G7		M4fqRlMhcA>?		NF7EV2VKSzVyIE2gNE4xPzN5IN88US=>	NIXTVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M{LKd\|czKGh?		NUX0NY82UUN3MDC9JFAvOTNizszN	NF7uXW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
A431	NF3YNpNHfW6ldHnvckBie3OjeR?=		NYe3Nm0{OSCq		Mn;XTWM2OCB;IECuNVQyKM7:TR?=	NHWzTZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
A549	MkLHSpVv[3Srb36gZZN{[Xl?				NETjVlZKSzVyIE2gNE4yPSEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
Calu3	M4fP[2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4jM[FczKGh?		NUDNT5VDT0l3MDC9JFAvOjZ2IN88US=>	M1LQblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9	NX7Y[o15TnWwY4Tpc44h[XO\|YYm=		M37UVFIxKG2rboO=		MmjOTWM2OCB;IECuNlc5KM7:TR?=	MkC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEKxOVEoRjJ6NEiyNVUyRC:jPh?=
BAF3	MYjGeY5kfGmxbjDhd5NigQ>?		NVHs[29FPzJiaB?=		MX\HTVUxKD1iMD6zJO69VQ>?	NUjte5VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NFyzNmpHfW6ldHnvckBie3OjeR?=		NITDPXc4OiCq		NWTLRZpST0l3MDC9JFAvOzFizszN	NEjVXYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H460	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NV\SdYJLPzJiaB?=		NYLsN3c2UUN3MDC9JFAvPDF3OTFOwG0>	NXLxZZUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
LoVo	M2LoVWZ2dmO2aX;uJIF{e2G7		NYKwTGllOiCq		NVX6R5N5UUN3MDC9JFAvPDhizszN	M2PaW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
LoVo	M172cWZ2dmO2aX;uJIF{e2G7		MWSyJIg>		MWLJR\|UxKD1iMD60PEDPxE1?	NFnCUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
A549	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NW[5OWNYPzJiaB?=		NHTpcpVKSzVyIE2gNE41QDZizszN	Mnn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
BAF3	MWrGeY5kfGmxbjDhd5NigQ>?		M1PC[VczKGh?		Mn73S2k2OCB;IECuOUDPxE1?	Ml70QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549	NHO4eGFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NH3BTog4OiCq		M4XPd2lEPTBiPTCwMlU{KM7:TR?=	M2HwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
A549	MlrrR5l1d3SxeHnjbZR6KGG\|c3H5		NWn3fJc5PzJiaB?=		MnvXTWM2OCB;IECuOVMh\|ryP	NGKzfW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
BAF3	NYXSOGJoTnWwY4Tpc44h[XO\|YYm=		M{PSbVczKGh?		NVjRUHl7T0l3MDC9JFAvPTVizszN	M{DPfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	Ml3sSpVv[3Srb36gZZN{[Xl?		NFPiO4U4OiCq		NXP0WlhTT0l3MDC9JFAvPTZizszN	NXfTclF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HEK293	NUDKclI5TnWwY4Tpc44h[XO\|YYm=				M4r4ZmlEPTBiPTCwMlU4KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
BAF3	NFHFW3BHfW6ldHnvckBie3OjeR?=		M3v6OVczKGh?		NFL6c3JIUTVyIE2gNE42QSEQvF2=	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A431	NH[yVlNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				MVrJR\|UxKD1iMD62NVU3KM7:TR?=	M2HKTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HT-29	NGjJ[FJEgXSxdH;4bYNqfHliYYPzZZk>		NWnOfFBVPzJiaB?=		MkHtTWM2OCB;IECuOlUh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431	Mkj5SpVv[3Srb36gZZN{[Xl?		NHnWSo46PiCq		NXf0SlNpTUN3MDC9JFAvPjZ5IN88US=>	NHvqZ449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyOVI3QSd-MkiyNlUzPjl:L3G+
A431	NUHBcYd2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3nhO\|k3KGh?		MXHFR\|UxKD1iMD62O{DPxE1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	MljPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MmWxO\|IhcA>?		M4rPfmlEPTBiPTCwMlY5PSEQvF2=	NInFbW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
A431	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M4DaNFk3KGh?		NVezRmtrTUN3MDC9JFAvPyEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyM{m5NUc,Ojh4MEO5PVE9N2F-
A549	Mn7oR5l1d3SxeHnjbZR6KGG\|c3H5		Mlf4O\|IhcA>?		MXvJR\|UxKD1iMD64O{DPxE1?	M1G3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
A431	NF;KZ4VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3fiXFczKGh?		NUD6do5sUUN3MDC9JFAvQDl\|IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
BA/F3	MmLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MkfuO\|IhcA>?		M1;nZ2lEPTBiPTCxJO69VQ>?	M3O0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3	NH[yNGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4nTcVczKGh?		NVX5OWRJT0l3MDC9JFEvOiEQvF2=	NGmxfVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H2122	NGezPYdHfW6ldHnvckBie3OjeR?=		M1z3NVczKGh?		NYrk[ZdrT0l3MDC9JFEvOiEQvF2=	NYeyTo5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A431	NYP6[2ZRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MkGyO\|IhcA>?		M1vZOmlEPTBiPTCxMlI1KM7:TR?=	NWfJSFdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
A431	NGS0[\|NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MlH2O\|IhcA>?		M1S5WmlEPTBiPTCxMlI3KM7:TR?=	M1LGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
A431	M2LPVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NYjsdm1[PzJiaB?=		NHTpWmFKSzVyIE2gNU43ODRizszN	MmjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O\|koRjJ6MEOzOVc6RC:jPh?=
A549	M3z0SWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NF3N[lA6PiCq		NFjHT\|hGSzVyIE2gNU45OyEQvF2=	NIDOdms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
CHL	MoLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVjmN5RVPzJiaB?=		MVjHTVUxKD1iMj65JO69VQ>?	MlTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1355	NGfO[\|RHfW6ldHnvckBie3OjeR?=		MXK3NkBp		NXLxeYtyT0l3MDC9JFMh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1703	M{nIS2Z2dmO2aX;uJIF{e2G7		NXTjN3dsPzJiaB?=		M33VXmdKPTBiPTCzMlUh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A549	MmC0SpVv[3Srb36gZZN{[Xl?		NELKSGM4OiCq		NG[xWmZIUTVyIE2gN{42KM7:TR?=	NV\UZ454RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO	NEDUUYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIf4fWE4OiCq		MU\HTVUxKD1iND6yJO69VQ>?	M170WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	MoDkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Mnr2O\|IhcA>?		NGrJcWNKSzVyIE2gOE43OSEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3	NVvzeXRwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MV:3NkBp		M1[1c2lEPTBiPTC1MlE2KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BEAS2B	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWK3NkBp		MoXhTWM2OCB;IEG0Mlkh\|ryP	M2LPcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975	M{ixdGZ2dmO2aX;uJIF{e2G7		MmLINkBp		MXnJR\|UxKD1iMUWg{txO	NXvkR2N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
PC9	MnvBSpVv[3Srb36gZZN{[Xl?		MU[yJIg>		MkHJTWM2OCB;IEG3JO69VQ>?	NIDNWIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
LoVo	MXrGeY5kfGmxbjDhd5NigQ>?		NF[0[YczKGh?		NE\uNFFKSzVyIE2gOFgxKM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	Mmr5RY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				Ml7FRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S5O\|BOKGSxdXLs[UBufXSjboSgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEAzNjVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm\|IILlcIF1cX[nIITvJINwdnS{b3y=	NH6zSVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
rat hepatocytes	MlnISpVv[3Srb36gZZN{[Xl?				Mn[0TY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK\|Yh[2WubIO=	M2qyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
human hepatocytes	NV3mVlJGTnWwY4Tpc44h[XO\|YYm=				M4fBeWlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNibXXhd5Vz\WRicHXyJFExLzZiY3XscJM>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	MUDBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	MlTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975	MnfLSpVv[3Srb36gZZN{[Xl?				MmLCV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B1dyCLQ{WwJIZweiC5aXzkJJR6eGViRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGE1OzFiY3XscJM>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	Ml\zRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MVzBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDFS2ZTKFR5OUDNM2w5PTiUIHTveYJt\SCvdYThcpQh\XiycnXzd4lv\yCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgfIVvd2e{YX\0[YQhcW5iQlHMRk9kKGG2aIntbYMhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkAzOSCmYYnz	M{jWPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827	MnvPRZBweHSxc3nzJIF{e2G7				M3ziTmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOg[YFzdHliYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEGuN\|QmMQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
HCC827	MlLQRZBweHSxc3nzJIF{e2G7				M3m2fGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOgcIF1\SCjcH;weI91cWNiY3XscJMh[XRiMzD1UUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWMWZKXENxcILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eTCoVpZjKD1iMkeuNVQmMQ>?	NYfKNWdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
A549	MlTDSpVv[3Srb36gZZN{[Xl?				NV;DU28{W2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MlroO\|IhcA>?		NHThN4RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|gzPyClZXzsd{BifCBzIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO\|I9N2F-
BAF3	M4LmbWZ2dmO2aX;uJIF{e2G7		NXriU5JiOiCq		NEjXOYtKdmirYnn0bY9vKG:oIFXHSnIhXDd7MF2vUFg2QFJxQ{e5O3MhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVITi2rbnT1Z4VlKHKnY3XweI9zKHCqb4PwbI9zgWyjdHnvckBifCBzIITvJFMhfU1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCHR1[gd5RqdXWuYYTpc44h\m:{IEG1JI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NHLDNZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
BAF3	M3L5PGZ2dmO2aX;uJIF{e2G7		MVeyJIg>		M1LaNGlvcGmkaYTpc44hd2ZiRVfGVkAyQURxVEe5NG0wSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
NCI-H1975	M1PzUGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				NUXG[phGSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IIjlco9oemGodHXkJIlvKFOWT1PLMWZwgG5zboWvUop2KG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dX3vdkBoem:5dHigZZQhOjBibXevb4cw\GG7LDDwc{By\CCob4KgNVQh\GG7czDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUKxPUc,Ojh\|OUWyNVk9N2F-
Caco2	NELnSIVHfW6ldHnvckBie3OjeR?=		MUiyJIg>		MkHZSYZndHW6IILheIlwKG:oIHHwdIFz\W62IIDldo1m[WKrbHn0fUBnem:vIHLhd49t[XSncnHsJJNq\GVidH:gZZBq[2GuIIPp[IUhd3[ncjDhdIlk[Wxic3nk[UB1dyCkYYPvcIF1\XKjbDDzbYRmKG:4ZYKgbY4hcHWvYX6gR4FkdzJiY3XscJMh[XRiNTD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
A431	MkPCSpVv[3Srb36gZZN{[Xl?				NV\vOGtIW2WuZXP0bZZqfHlicnH0bY8hd2ZiRVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZTKHSxIFXDOVAh\m:{IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUj3MPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62	MofWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
Caco2	M{fzTWZ2dmO2aX;uJIF{e2G7		NEnE[WIzKGh?		NX7oRWxRSXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCjcHnjZYwhfG9iYnHzc4xifGW{YXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO=	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
Caco2	MnLXSpVv[3Srb36gZZN{[Xl?		MnjENkBp		NUX1d2x[SXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCkYYPvcIF1\XKjbDD0c{BieGmlYXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO=	NGjiR\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	MnXtSpVv[3Srb36gZZN{[Xl?		NECzOGc1KGh?		M2\mS2lvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MmfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	NIflbYlHfW6ldHnvckBie3OjeR?=		Ml35OEBp		M2jIU2lvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJI12fGGwdDDpckBpfW2jbjDIR2M5OjdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5N1OnckS3N{B{cXSnIHH0JFEhfU1ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	Mm\pRZBweHSxc3nzJIF{e2G7		NITKVGw1QCCq		NIXuSWFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\TNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	NYm5V2pMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	NXzGWY9nSXCxcITvd4l{KGG\|c3H5		NYr4NmVXPDhiaB?=		MX3JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	Mnr2RZBweHSxc3nzJIF{e2G7		M{Hu[VQ5KGh?		M4fFcmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255	MXHBdI9xfG:\|aYOgZZN{[Xl?		M{n1e\|Q5KGh?		MofXTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKM{K1OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4VkBufXSjboSgZZN{\XO\|ZXSgZZMh[2G\|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	MWPBdI9xfG:\|aYOgZZN{[Xl?		M3zjb\|Q5KGh?		MoDnTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	NU\hSXJFSXCxcITvd4l{KGG\|c3H5		MVy0PEBp		NWfxXI1LUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDQR\|kh[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	NXHFbI0zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	NULHT4w2SXCxcITvd4l{KGG\|c3H5		NWjaeppyPDhiaB?=		M3Ll[Wlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	MljFRZBweHSxc3nzJIF{e2G7		NYK3ZmJlPDhiaB?=		MYHJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NUjkU3dkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	M3TNZmZ2dmO2aX;uJIF{e2G7				M{e3dnNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNiaHHyZo9zcW6pIIfpcIQufHmyZTDFS2ZT	M1r5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
human hepatocytes	NXTxXo9NTnWwY4Tpc44h[XO\|YYm=				MUTJcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	MmjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
rat hepatocytes	NYfhSoF1TnWwY4Tpc44h[XO\|YYm=				NH;5XWRKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgcYltdGmxbjDj[Yxtew>?	MkDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
A549, NCI-H1975	NUTzSFllTnWwY4Tpc44h[XO\|YYm=				NE\jOXNU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHN?	MkGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
A549, PC9	M1;YUGZ2dmO2aX;uJIF{e2G7				NYfr[4dUW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiRVfGMZN1cW23bHH0[YQhf2muZDD0fZBmKEWJRmKgbY4hcHWvYX6gRVU1QSClZXzsd{B1dyCLQ{WwJIZweiCHR1\SJIRmdGW2aX;uJI12fGGwdDDpckBpfW2jbjDQR\|kh[2WubIO=	M4DL[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827	MkDiRZBweHSxc3nzJIF{e2G7				Mnm3TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0OkB1dyCDN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bm[XKueTDhdI9xfG:2aXOgZ4VtdHNiYYSgN{B2VSCjZoTldkAzPCCqcoOgZpkhSW6wZYjpckBXNU[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfUApWn[kIE2gNU4{PCC2bzCxMlY4LSl?	NE\HZmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975	NUHyR4ZzTnWwY4Tpc44h[XO\|YYm=				MWLJcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gSWdHNXO2aX31cIF1\WRiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF1KDFidH:gNVAxKG6PIHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	M3q5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUC2NVE1Lz5{OUmwOlEyPDxxYU6=
A431	NHHSXoJHfW6ldHnvckBie3OjeR?=				NY\4SW9GW2WuZXP0bZZqfHlicnH0bY8tKHKjdHnvJGlEPTBiZn;yJIh2dWGwIFG0N\|Eh[2WubIOgc5ZmemW6cILld5Nqdmdid3ns[E11gXCnIFXHSnIhfG9iSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIV5eHKnc4PpcochTUeIUjDUO\|kxVS:OOEW4VkBufXSjboS=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
PC9	NU\6TXRXSW62aYT1cY9zKGGldHn2bZR6KGG\|c3H5				MljyRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMDDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MmmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431	MmTLRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				M3vu[WFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内研究

AZD9291（5mg / kg p.o.）引起整个EGFRm+（PC9）和EGFRm+/ T790M（H1975）肿瘤模型肿瘤中显著的肿瘤消退，伴随着对体内EGFR磷酸化和下游关键信号通路，如AKT和ERK的显著抑制。^[2]

动物实验： ^[2]	- 合并 Animal Models: PC9和H1975移植瘤小鼠 Dosages: ~5 毫克/千克 Administration: p.o. (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	99 mg/mL warmed (198.15 mM)
	Water	Insoluble
	Ethanol	'43 mg/mL warmed
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	7.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Osimertinib (AZD9291) SDF

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS号	1421373-65-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Mereletinib

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Unknown status	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

研究领域

产品类型

定制您的化合物库

Osimertinib (AZD9291)

客户使用Selleck生产的Osimertinib (AZD9291)发表文献261篇：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Osimertinib (AZD9291) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

相关EGFR产品